DrugPatentWatch Database Preview
Rb Hlth Company Profile
What is the competitive landscape for RB HLTH, and when can generic versions of RB HLTH drugs launch?
RB HLTH has four approved drugs.
There are three US patents protecting RB HLTH drugs.
There are thirty-seven patent family members on RB HLTH drugs in nineteen countries and six supplementary protection certificates in five countries.
Drugs and US Patents for Rb Hlth
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rb Hlth | MUCINEX | guaifenesin | TABLET, EXTENDED RELEASE;ORAL | 021282-001 | Jul 12, 2002 | OTC | Yes | No | 6,372,252 | ➤ Sign Up | ➤ Sign Up | ||||
Rb Hlth | MUCINEX | guaifenesin | TABLET, EXTENDED RELEASE;ORAL | 021282-001 | Jul 12, 2002 | OTC | Yes | No | 7,838,032 | ➤ Sign Up | Y | ➤ Sign Up | |||
Rb Hlth | MUCINEX | guaifenesin | TABLET, EXTENDED RELEASE;ORAL | 021282-002 | Dec 18, 2002 | OTC | Yes | Yes | 6,372,252 | ➤ Sign Up | ➤ Sign Up | ||||
Rb Hlth | MUCINEX D | guaifenesin; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021585-001 | Jun 22, 2004 | OTC | Yes | No | 6,955,821 | ➤ Sign Up | Y | ➤ Sign Up | |||
Rb Hlth | MUCINEX DM | dextromethorphan hydrobromide; guaifenesin | TABLET, EXTENDED RELEASE;ORAL | 021620-002 | Apr 29, 2004 | OTC | Yes | No | 7,838,032 | ➤ Sign Up | Y | ➤ Sign Up | |||
Rb Hlth | MUCINEX DM | dextromethorphan hydrobromide; guaifenesin | TABLET, EXTENDED RELEASE;ORAL | 021620-001 | Apr 29, 2004 | OTC | Yes | Yes | 7,838,032 | ➤ Sign Up | Y | ➤ Sign Up | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Rb Hlth
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Rb Hlth | DELSYM | dextromethorphan polistirex | SUSPENSION, EXTENDED RELEASE;ORAL | 018658-001 | Oct 8, 1982 | 4,221,778 | ➤ Sign Up |
Rb Hlth | DELSYM | dextromethorphan polistirex | SUSPENSION, EXTENDED RELEASE;ORAL | 018658-001 | Oct 8, 1982 | 5,980,882 | ➤ Sign Up |
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for RB HLTH drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Suspension | 30 mg/5 mL | ➤ Subscribe | 2009-01-12 |
➤ Subscribe | Extended-release Tablets | 600 mg/30 mg and 1200 mg/60 mg | ➤ Subscribe | 2008-12-17 |
➤ Subscribe | Extended-release Tablets | 600 mg and 1.2 gm | ➤ Subscribe | 2006-06-09 |
International Patents for Rb Hlth Drugs
Country | Document Number | Estimated Expiration |
---|---|---|
New Zealand | 521959 | ➤ Sign Up |
Japan | 2003531849 | ➤ Sign Up |
Taiwan | I314866 | ➤ Sign Up |
Hong Kong | 1052651 | ➤ Sign Up |
South Africa | 200409171 | ➤ Sign Up |
Portugal | 1276467 | ➤ Sign Up |
Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Rb Hlth Drugs
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
13/055 | Ireland | ➤ Sign Up | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624 |
C0062 | France | ➤ Sign Up | PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626 |
323 | Luxembourg | ➤ Sign Up | PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624 |
/2013 | Austria | ➤ Sign Up | PRODUCT NAME: KOMBINATION VON A) DEXTROMETHORPHAN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, BEISPIELSWEISE DEXTROMETHORPHANHYDROBROMID, UND INSBESONDERE DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT UND B) CHINIDIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, BEISPIELSWEISE CHINIDINSULFAT, UND INSBESONDERE CHINIDINSULFATDIHYDRAT.; REGISTRATION NO/DATE: EU/1/13/833 20130626 |
2013 00059 | Denmark | ➤ Sign Up | PRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624 |
2013 00059 | Denmark | ➤ Sign Up | PRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624 |
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.